Bonesupport Holding AB/Skr BONEX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Bonesupport Holding AB
Bonesupport Holding AB, founded in 1999 and headquartered in Lund, Sweden, specializes in developing and commercializing injectable bio-ceramic bone graft substitutes under the CERAMENT® brand. These products are designed to remodel into the patient's own bone and can elute drugs directly into bone voids. The company's portfolio includes CERAMENT® Bone Void Filler, CERAMENT® G, and CERAMENT® V, targeting conditions such as bone voids resulting from trauma, infection, or disease. In 2024, Bonesupport reported net sales of SEK 898.7 million, marking a 52% increase from the previous year. The company operates in Europe, North America, and other international markets, focusing on orthobiologics for bone injury management.
- Ticker
- Skr BONEX
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 174
- Headquarters
- Lund, Sweden
- Website
- www.bonesupport.com
BONEX Metrics
BasicAdvanced
kr 21B
79.58
kr 4.08
0.31
-
Price and volume
Market cap
kr 21B
Beta
0.31
52-week high
kr 340.20
52-week low
kr 165.00
Average daily volume
451K
Financial strength
Current ratio
5.73
Quick ratio
4.275
Long term debt to equity
0.003
Total debt to equity
0.011
Interest coverage (TTM)
17.41%
Profitability
EBITDA (TTM)
359.196
Gross margin (TTM)
91.85%
Net profit margin (TTM)
19.40%
Operating margin (TTM)
25.49%
Effective tax rate (TTM)
24.29%
Revenue per employee (TTM)
kr 8,050,000
Management effectiveness
Return on assets (TTM)
20.56%
Return on equity (TTM)
29.73%
Valuation
Price to earnings (TTM)
79.578
Price to revenue (TTM)
15.214
Price to book
21.36
Price to tangible book (TTM)
21.69
Price to free cash flow (TTM)
64.919
Free cash flow yield (TTM)
1.54%
Free cash flow per share (TTM)
5
Growth
Revenue change (TTM)
25.20%
Earnings per share change (TTM)
78.98%
3-year revenue growth (CAGR)
39.01%
3-year earnings per share growth (CAGR)
7.74%
What the Analysts think about BONEX
Analyst ratings (Buy, Hold, Sell) for Bonesupport Holding AB stock.
Analyst projections of the future price of Bonesupport Holding AB stock.
Bulls say / Bears say
Third-quarter sales grew 38% at constant exchange rates, while adjusted operating profit rose to SEK 139.3 million from SEK 78.6 million. This points to strong demand and growing operating leverage. (BONESUPPORT)
US CMS confirmed higher-paying DRG assignments for qualifying CERAMENT G cases, effective from 1 October 2026. Better hospital reimbursement could make the product easier to adopt in complex orthopaedic infections. (BONESUPPORT)
The SOLARIO study reported that local antibiotic treatment can allow systemic antibiotics to be reduced from weeks to days without worse outcomes. This supports the broader treatment approach used by BONESUPPORT’s antibiotic-eluting products. (BONESUPPORT)
The FDA extended the deadline for additional CERAMENT V data, and BONESUPPORT submitted the package in September. The extra review steps leave the timing of US approval uncertain. (BONESUPPORT)
Some US hospitals introduced pre-approval checks to control near-term costs, slowing CERAMENT G growth below BONESUPPORT’s expectations in Q2. Wider adoption therefore depends partly on hospitals accepting the product’s cost and clinical value. (Stock Analysis)
Currency translation reduced reported growth: sales rose 26% in the first nine months of 2026, compared with 33% at constant exchange rates. A stronger Swedish krona can therefore make underlying demand translate into weaker SEK revenue growth. (BONESUPPORT)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
BONEX Financial Performance
Revenues and expenses
BONEX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing BONEX
AllUSDEURGBP
Fund name | Fund size | Skr BONEX weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.17% |
iShares Ageing Population£AGES | $953M | 0.17% |
iShares Ageing Population€AGED | $903M | 0.17% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.08% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.